Thursday, December 30, 2010

FDA Approves Merck Gardasil for Anal Cancer: Deadly Choices?

December 30, 2010 Published in AGE OF AUTISM

SANEVAX Questions the FDA Approval of Merck's Gardasil for anal cancer. Dr. Julie Gerberding, head of the vaccine division for Merck, was the head of the CDC under President Bush, and was responsible for the pediatric vaccine schedule, which included adding Dr. Paul Offit's Merck vaccine RotaTeq during her watch. From SANEVAX, a watchdog group concerned with adverse reactions, including death, from the genital wart vaccine called Gardasil (and it's competitor from GlaxoSmithKline Cevarix.)

...According to the National Cancer Institute, an estimated 5,260 people will be diagnosed with anal cancer in 2010 (United States). 720 fatalities due to anal cancer are anticipated. The average age at diagnosis is 60. The data presented in a 1996 study indicates you are over 10 times more likely to die from an overdose of over-the-counter pain medications, such as aspirin, than you are to die of anal cancer. Merck made no mention of these facts anywhere in the documentation they presented to the FDA.

SaneVax wants to know, “In what universe does this make a convincing argument for vaccinating people ages 9 to 26?”

Read the full story at

No comments:

Post a Comment